{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:25:43Z","timestamp":1780093543884,"version":"3.54.0"},"reference-count":63,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T00:00:00Z","timestamp":1719100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HSF Pharmaceuticals SA","award":["PID2021-126325OB-I00"],"award-info":[{"award-number":["PID2021-126325OB-I00"]}]},{"name":"HSF Pharmaceuticals SA","award":["P2022\/BMD-7406"],"award-info":[{"award-number":["P2022\/BMD-7406"]}]},{"name":"MCIN\/AEI\/10.13039\/501100011033","award":["PID2021-126325OB-I00"],"award-info":[{"award-number":["PID2021-126325OB-I00"]}]},{"name":"MCIN\/AEI\/10.13039\/501100011033","award":["P2022\/BMD-7406"],"award-info":[{"award-number":["P2022\/BMD-7406"]}]},{"name":"ERDF A way of making Europe","award":["PID2021-126325OB-I00"],"award-info":[{"award-number":["PID2021-126325OB-I00"]}]},{"name":"ERDF A way of making Europe","award":["P2022\/BMD-7406"],"award-info":[{"award-number":["P2022\/BMD-7406"]}]},{"name":"Autonomous Community of Madrid, Spain","award":["PID2021-126325OB-I00"],"award-info":[{"award-number":["PID2021-126325OB-I00"]}]},{"name":"Autonomous Community of Madrid, Spain","award":["P2022\/BMD-7406"],"award-info":[{"award-number":["P2022\/BMD-7406"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Vaccination with transiently activated replication-competent controlled herpesviruses (RCCVs) expressing influenza A virus hemagglutinins broadly protects mice against lethal influenza virus challenges. The non-replicating RCCVs can be activated to transiently replicate with high efficiency. Activation involves a brief heat treatment to the epidermal administration site in the presence of a drug. The drug co-control is intended as a block to inadvertent reactivation in the nervous system and, secondarily, viremia under adverse conditions. While the broad protective effects observed raise an expectation that RCCVs may be developed as universal flu vaccines, the need for administering a co-activating drug may dampen enthusiasm for such a development. To replace the drug co-control, we isolated keratin gene promoters that were active in skin cells but inactive in nerve cells and other cells in vitro. In a mouse model of lethal central nervous system (CNS) infection, the administration of a recombinant that had the promoter of the infected cell protein 8 (ICP8) gene of a wild-type herpes simplex virus 1 (HSV-1) strain replaced by a keratin promoter did not result in any clinical signs, even at doses of 500 times wild-type virus LD50. Replication of the recombinant was undetectable in brain homogenates. Second-generation RCCVs expressing a subtype H1 hemagglutinin (HA) were generated in which the infected cell protein 4 (ICP4) genes were controlled by a heat switch and the ICP8 gene by the keratin promoter. In mice, these RCCVs replicated efficiently and in a heat-controlled fashion in the epidermal administration site. Immunization with the activated RCCVs induced robust neutralizing antibody responses against influenza viruses and protected against heterologous and cross-group influenza virus challenges.<\/jats:p>","DOI":"10.3390\/vaccines12070703","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T10:41:12Z","timestamp":1719225672000},"page":"703","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Broad Influenza Vaccine Based on a Heat-Activated, Tissue-Restricted Replication-Competent Herpesvirus"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4473-4498","authenticated-orcid":false,"given":"Nuria","family":"Vilaboa","sequence":"first","affiliation":[{"name":"Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain"},{"name":"CIBER de Bioingenieria, Biomateriales y Nanomedicina, CIBER-BBN, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5935-8494","authenticated-orcid":false,"given":"David C.","family":"Bloom","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics & Microbiology, University of Florida College of Medicine, Gainesville, FL 32610-0266, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Canty","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics & Microbiology, University of Florida College of Medicine, Gainesville, FL 32610-0266, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4183-0871","authenticated-orcid":false,"given":"Richard","family":"Voellmy","sequence":"additional","affiliation":[{"name":"HSF Pharmaceuticals SA, 1814 La Tour-de-Peilz, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/14760584.2015.1013941","article-title":"A novel approach for addressing diseases not yielding to effective vaccination? Immunization by replication-competent controlled virus","volume":"14","author":"Voellmy","year":"2015","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_2","first-page":"286","article-title":"Immunization by replication-competent controlled viral pathogen\u2014A novel approach worth exploring for diseases refractory to effective conventional vaccination?","volume":"6","author":"Voellmy","year":"2015","journal-title":"Vaccines Vaccin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10200","DOI":"10.1128\/JVI.79.16.10200-10209.2005","article-title":"Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies","volume":"79","author":"Peng","year":"2005","journal-title":"J. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1743-422X-3-44","article-title":"ICP0 antagonizes Stat I-dependent repression of herpes simplex virus: Implications for the regulation of viral latency","volume":"3","author":"Halford","year":"2008","journal-title":"Virol. J."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Huang, X., Lu, B., Yu, W., Fang, Q., Liu, L., Zhuang, K., Shen, T., Wang, H., Tian, P., and Zhang, L. (2009). A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004180"},{"key":"ref_6","first-page":"2479","article-title":"The family Herpesviridae. A brief introduction","volume":"Volume 2","author":"Fields","year":"1996","journal-title":"Fields Virology"},{"key":"ref_7","first-page":"2501","article-title":"Herpes simplex viruses and their replication","volume":"Volume 2","author":"Fields","year":"1996","journal-title":"Fields Virology"},{"key":"ref_8","first-page":"369","article-title":"HSV vectors for gene therapy","volume":"10","author":"Bloom","year":"1998","journal-title":"Methods Mol. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ymthe.2005.03.029","article-title":"Novel gene switches for targeted and timed expression of proteins of interest","volume":"12","author":"Vilaboa","year":"2005","journal-title":"Mol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10668","DOI":"10.1128\/JVI.01667-15","article-title":"Replication-competent controlled herpes simplex virus","volume":"89","author":"Bloom","year":"2015","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e00616-8","DOI":"10.1128\/JVI.00616-18","article-title":"Immunization by replication-competent controlled herpesvirus vectors","volume":"92","author":"Bloom","year":"2018","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bloom, D.C., Lilly, C., Canty, W., Vilaboa, N., and Voellmy, R. (2024). Very broadly effective hemagglutinin-directed influenza vaccines with anti-herpetic activity. Vaccines, 12.","DOI":"10.3390\/vaccines12050537"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","article-title":"The human antibody response to influenza A virus infection and vaccination","volume":"19","author":"Krammer","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1093\/nar\/15.11.4491","article-title":"Activities of herpes simplex virus type 1 (HSV-1) ICP4 genes specifying nonsense peptides","volume":"15","author":"DeLuca","year":"1987","journal-title":"Nucleic Acids Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/978-1-4939-0758-8_35","article-title":"Equine influenza culture methods","volume":"1161","author":"Chambers","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1006\/dbio.1999.9417","article-title":"Ubiquitous expression of marker transgenes in mice and rats","volume":"214","author":"Kisseberth","year":"1999","journal-title":"Dev. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wang, S., Luo, Z., Zhang, Y., Yuan, D., Ge, W., and Wang, X. (2018). The inconsistent regulation of HOXC13 on different keratins and the regulation mechanism on HOXC13 in cashmere goat (Capra hircus). BMC Genom., 19.","DOI":"10.1186\/s12864-018-5011-4"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1128\/iai.16.2.717-719.1977","article-title":"Efficacy of herpes simplex virus type 1 immunization in protecting against acute and latent infection by herpes simplex type 2 in mice","volume":"16","author":"McKendall","year":"1977","journal-title":"Infect. Immun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1261\/rna.2309906","article-title":"Control of mammalian translation by mRNA structure near caps","volume":"12","author":"Babendure","year":"2006","journal-title":"RNA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/170.5.1100","article-title":"Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1","volume":"170","author":"McLean","year":"1994","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1126\/science.1192517","article-title":"Induction of broadly neutralizing H1N1 influenza antibodies by vaccination","volume":"329","author":"Wei","year":"2010","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self- assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/mBio.00018-10","article-title":"Influenza virus vaccine based on the conserved hemagglutinin stalk domain","volume":"1","author":"Steel","year":"2010","journal-title":"MBio"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-018-0063-7","article-title":"Minihemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge","volume":"3","author":"Huizingh","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"E2514","DOI":"10.1073\/pnas.1402766111","article-title":"Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection","volume":"111","author":"Mallajosyula","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"22666","DOI":"10.1038\/srep22666","article-title":"Stalking influenza by vaccination with pre-fusion headless HA mini-stem","volume":"6","author":"Valkenburg","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1128\/JVI.00641-13","article-title":"Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies","volume":"87","author":"Krammer","year":"2013","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.1128\/JVI.01715-13","article-title":"Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses","volume":"87","author":"Margine","year":"2013","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e00286-17","DOI":"10.1128\/JVI.00286-17","article-title":"Chimeric hemagglutinin constructs induce broad protection against influenza B virus challenge in the mouse model","volume":"91","author":"Ermler","year":"2017","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.vaccine.2018.02.019","article-title":"Genetic and subunit vaccines based on the stem domain of the equine influenza hemagglutinin provide homosubtypic protection against heterologous strains","volume":"36","author":"Caldevilla","year":"2018","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/infdis\/jiy711","article-title":"Universal influenza virus vaccines that target the conserved hemagglutinin stalk and conserved sites in the head domain","volume":"219","author":"Krammer","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41541-019-0126-4","article-title":"A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains","volume":"4","author":"Broecker","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/mi.2014.59","article-title":"Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes","volume":"8","author":"Fan","year":"2015","journal-title":"Mucosal Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.vaccine.2011.01.100","article-title":"A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets","volume":"29","author":"Giles","year":"2011","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1128\/JVI.03152-15","article-title":"Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses","volume":"90","author":"Carter","year":"2016","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Allen, J.D., Ray, S., and Ross, T.M. (2018). Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0210043"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"eabo2167","DOI":"10.1126\/scitranslmed.abo2167","article-title":"An inactivated multivalent influenza A virus vaccine is broadly protective in mice and ferrets","volume":"14","author":"Park","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"779223","DOI":"10.3389\/fimmu.2021.779223","article-title":"A host-restricted self-attenuated influenza virus provides broad pan-influenza A protection in a mouse model","volume":"12","author":"Kim","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12192-018-0875-4","article-title":"Targeted heat activation of HSP promoters in the skin of mammalian animals and humans","volume":"23","author":"Voellmy","year":"2018","journal-title":"Cell Stress. Chaperones"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/21645515.2015.1066050","article-title":"Duality at the gate: Skin dendritic cells as mediators of vaccine immunity and tolerance","volume":"12","author":"Nirschl","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-020-00265-5","article-title":"Epicutaneous immunization with modified Vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge","volume":"6","author":"Pan","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1016\/j.vaccine.2015.02.074","article-title":"A microneedle patch containing measles vaccine is immunogenic in non-human primates","volume":"33","author":"Edens","year":"2015","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Xie, Y., Wu, L., Wang, M., Cheng, A., Yang, Q., Wu, Y., Jia, R., Zhu, D., Zhao, X., and Chen, S. (2019). Alpha-herpesvirus thymidine kinase genes mediate viral virulence and are potential therapeutic targets. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.00941"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S0022172400025109","article-title":"The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice","volume":"81","author":"Field","year":"1978","journal-title":"J. Hyg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e01979-16","DOI":"10.1128\/JVI.01979-16","article-title":"Thymidine kinase-negative herpes simplex Virus 1 Can efficiently establish persistent infection in neural tissues of nude mice","volume":"91","author":"Huang","year":"2017","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Joyce, J.D., Patel, A.K., Murphy, B., Carr, D.J.J., Gershburg, E., and Bertke, A.S. (2021). Assessment of two novel live-attenuated vaccine candidates for herpes simplex virus 2 (HSV-2) in guinea pigs. Vaccines, 9.","DOI":"10.3390\/vaccines9030258"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Stanfield, B.A., Stahl, J., Chouljenko, V.N., Subramanian, R., Charles, A.-S., Saied, A.A., Walker, J.D., and Kousoulas, K.G. (2014). A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0109890"},{"key":"ref_52","first-page":"116","article-title":"Better targeting, better efficiency for wide-scale neuronal transduction with the synapsin promoter and AAV-PHP.B","volume":"9","author":"Jackson","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e00812-8","DOI":"10.1128\/JVI.00812-18","article-title":"In vivo knockdown of the herpes simplex virus 1 latency-associated transcript reduces reactivation from latency","volume":"92","author":"Watson","year":"2018","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"eabm5658","DOI":"10.1126\/science.abm5658","article-title":"Multimodal control of dendritic cell functions by nociceptors","volume":"379","author":"Hanc","year":"2023","journal-title":"Science"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/JVI.76.8.3678-3687.2002","article-title":"Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity","volume":"76","author":"Brockman","year":"2002","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.gt.3301003","article-title":"Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice","volume":"6","author":"Chahlavi","year":"1999","journal-title":"Gene Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1089\/10430340050207957","article-title":"Effects of preexisting immunity on the response to herpes simplex-based oncolytic therapy","volume":"11","author":"Delman","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1128\/JVI.76.11.5565-5580.2002","article-title":"Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses","volume":"76","author":"Hocknell","year":"2002","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1006\/mthe.2000.0133","article-title":"Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model","volume":"2","author":"Lambright","year":"2000","journal-title":"Mol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/sj.gt.3300643","article-title":"Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector","volume":"5","author":"Herrlinger","year":"1998","journal-title":"Gene Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1099\/vir.0.81104-0","article-title":"Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity","volume":"86","author":"Lauterbach","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.virol.2006.08.015","article-title":"Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector","volume":"357","author":"Watanabe","year":"2007","journal-title":"Virology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e2110714118","DOI":"10.1073\/pnas.2110714118","article-title":"A recombinant herpes virus expressing influenza hemagglutinin confers protection and induces antibody-dependent cellular cytotoxicity","volume":"118","author":"Kaugars","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/7\/703\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:03:06Z","timestamp":1760108586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/7\/703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,23]]},"references-count":63,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["vaccines12070703"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12070703","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,23]]}}}